analyz
chang
immunolog
valu
time
hospit
patient
pandem
level
increas
day
ill
onset
decreas
baselin
level
level
virusspecifi
c
antibodi
undetect
day
ill
onset
peak
day
later
mm
patient
repres
total
lymphocyt
count
patient
tabl
tlymphocyt
count
cellsmm
patient
repres
total
lymphocyt
count
patient
tlymphocyt
count
cellsmm
patient
bcell
count
cellsmm
patient
natur
killer
cell
repres
lymphocyt
count
patient
fourteen
patient
ratio
less
standard
refer
ratio
flow
cytometr
result
show
develop
peripher
blood
lymphocyt
subset
diseas
cours
divid
group
basi
time
ill
onset
date
blood
sampl
collect
day
group
use
longest
time
onset
ill
hospit
day
patient
peak
temperatur
patient
observ
day
ill
onset
mean
count
percentag
tand
blymphocyt
subset
increas
day
ill
compar
result
obtain
fi
rst
day
ill
figur
howev
increas
b
cell
signifi
cant
anoth
studi
show
decreas
b
cell
day
symptom
onset
patient
pandem
healthi
person
result
show
impair
adapt
immun
respons
gradual
increas
recoveri
mildli
affect
patient
measur
serum
cytokin
concentr
hemagglutin
inhibit
hai
antibodi
titer
patient
hospit
followup
period
figur
observ
increas
level
day
ill
onset
higher
baselin
level
increas
level
level
decreas
baselin
level
day
ill
onset
although
level
day
ill
onset
higher
level
day
ill
onset
maximum
level
day
symptom
onset
higher
baselin
level
level
decreas
valu
lower
baselin
level
within
day
gradual
increas
baselin
level
day
ill
onset
serum
level
relat
patient
temperatur
day
symptom
onset
peak
temperatur
diseas
period
fever
level
show
minor
differ
relat
cough
sore
throat
patient
patient
hai
antibodi
titer
titer
day
ill
onset
hai
geometr
mean
titer
increas
day
symptom
onset
compar
day
symptom
onset
continu
increas
reach
peak
level
day
symptom
onset
increas
peak
hai
antibodi
titer
increas
observ
patient
bermejomartin
et
al
report
increas
serum
level
tumor
necrosi
patient
pandem
fi
rst
day
symptom
onset
differ
level
cytokin
observ
patient
mild
diseas
control
howev
similar
anoth
report
detect
increas
level
patient
mild
diseas
fi
rst
day
symptom
onset
differ
pattern
may
caus
differ
interv
time
symptom
onset
date
sampl
collect
day
vs
day
level
studi
quickli
decreas
baselin
level
day
symptom
onset
result
suggest
serum
median
pgml
serum
hai
antibodi
titer
transform
use
natur
logarithm
shown
mean
baselin
cytokin
concentr
yaxi
valu
healthi
person
p
hai
antibodi
level
compar
day
level
compar
baselin
level
compar
day
valu
compar
time
point
valu
compar
day
level
may
increas
patient
pandem
within
fi
rst
day
symptom
onset
follow
decreas
baselin
level
day
symptom
onset
patient
mild
diseas
continu
increas
sever
affect
patient
associ
antivir
immun
respons
infl
uenza
infect
howev
continu
excess
releas
three
day
ill
onset
like
contribut
seriou
pulmonari
infl
ammat
tissu
injuri
document
sever
acut
respiratori
syndrom
pandem
infl
uenza
releas
could
temper
product
proport
person
year
age
increas
hai
titer
receiv
dose
monoval
pandem
nonadjuv
vaccin
proport
increas
hai
titer
result
similar
recent
studi
howev
geometr
mean
titer
healthi
vaccin
person
increas
prevaccin
titer
greater
patient
natur
infect
pandem
viru
fi
nding
may
result
impair
adapt
immun
respons
pandem
viru
initi
phase
includ
decreas
number
b
lymphocyt
increas
regulatori
cell
conclus
data
indic
chang
cellular
profi
le
pandem
viru
infect
show
transient
product
main
effector
earli
innat
immun
respons
pandem
viru
indic
adapt
immun
respons
impair
initi
phase
infect
factor
may
help
clarifi
pathogenesi
pandem
viru
provid
new
approach
overcom
sever
infect
